REVELATION BIOSCIENCES, INC.

Rule 10b5-1 Trading Arrangements

During the three months ended March 31, 2026, each of the Company’sdirectors and executive officers adopted a “Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Each of the arrangements was entered into on or about January 28, 2026 and provides for the sale by the Company's broker of shares of the Company's common stock issued upon the vesting of restricted stock awards (“RSAs”) and restricted stock units (the “RSUs”), granted under the Company's 2021 Equity Incentive Plan, solely to satisfy tax withholding obligations associated with such vesting. The aggregate number of shares to be sold under each arrangement is not presently determinable, as it depends on the applicable tax withholding rate at the time of each vesting event. Each arrangement will terminate upon the final vesting of the RSAs and RSUs covered thereby, which is scheduled to occur on or before January 8, 2028.

No director or officer adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended March 31, 2026.